Current Perspective on MDMA-Assisted Psychotherapy for PTSD

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5917000/

Abstract:

The present paper discusses the current literature with regard to substance-assisted psychotherapy with Methylenedioxymethamphetamine (MDMA) for posttraumatic stress disorder (PTSD). The aim of the paper is to give a comprehensive overview of the development from MDMA’s early application in psychotherapy to its present and future role in the treatment of PTSD. It is further attempted to increase the attention for MDMA’s therapeutic potential by providing a thorough depiction of the scientific evidence regarding its theorized mechanism of action and potential harms of its application in the clinical setting (e.g., misattribution of therapeutic gains to medication instead of psychological changes). Empirical support for the use of MDMA-assisted psychotherapy, including the randomized, double-blind, placebo-controlled trails that have been conducted since 2008, is discussed. Thus far, an overall remission rate of 66.2% and low rates of adverse effects have been found in the six phase two trials conducted in clinical settings with 105 blinded subjects with chronic PTSD. The results seem to support MDMA’s safe and effective use as an adjunct to psychotherapy. Even though preliminary studies may look promising, more studies of its application in a psychotherapeutic context are needed in order to establish MDMA as a potential adjunct to therapy.

"In summary, preliminary results regarding MDMA-assisted psychotherapy for PTSD look promising and warrant further investigation. If future phase-three trials may indeed replicate these findings implication of an efficient adjunct to psychotherapy is indispensible. MDMA may provide a bridge to effectively overcome the gap between psychotherapy and psychopharmacology, thereby facilitating the integration of a more holistic approach to psychopathology"

https://maps.org/research/mdma/mdma-research-timeline

Open-Label Lead-In Study of MDMA-Assisted Psychotherapy for PTSD (United States and Canada)

Written on November 9, 2018.

An Open-Label, Multi-Site Phase 2 Study of the Safety and Effect of Manualized MDMA-Assisted Psychotherapy for the Treatment of Severe Posttraumatic Stress Disorder (United States and Canada)

The MAPS-sponsored Phase 2 open-label lead-in study of MDMA-assisted psychotherapy for posttraumatic stress disorder (PTSD) is taking place at planned Phase 3 sites across the United States and Canada. The purpose of this study is to provide the final training for our co-therapy teams in preparation for Phase 3 trials. The study will gather supportive data on the safety and effect of manualized MDMA-assisted psychotherapy while providing an opportunity for clinical supervision to planned Phase 3 therapy teams. Each co-therapy team will work with a single participant at their respective study site with supervision provided by MAPS' therapy training team.

Locations:

Los Angeles, CA | private practice

San Francisco, CA | research institution

San Francisco, CA | private practice

Boulder, CO | private practice

Fort Collins, CO | private practice

New Orleans, LA | private practice

New York, NY | research institution

New York, NY | private practice

Charleston, SC | private practice

Madison, WI | research institution

Boston, MA | private practice

Montreal, Canada | private practice

Vancouver, Canada | research institution

Israel | private practice

And other related mdma-research-timeline articles.

.

.

.

I see you have two ongoing threads on MDMA, so might as well include this here as well.

More on it here.  Not my bag, I don't think, lol, but very interesting nonetheless.  Who'd have thunk, eh?

 

http://www.benzobuddies.org/forum/index.php?topic=155161.0

 

http://www.benzobuddies.org/forum/index.php?topic=207647.0